Roth Capital resumed coverage of Stereotaxis (STXS) with a Buy rating and $4 price target The firm believes the company is positioned for long-term revenue growth and profitability from continued adoption of its Robotic Magnetic Navigation technology along with “imminent” regulatory approvals and subsequent commercial launches of its product pipeline.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STXS:
- Stereotaxis announces EU launch, 510k submission for Synchrony system
- Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today
- Strategic Collaboration and Market Expansion Drive Buy Rating for Stereotaxis
- Stereotaxis, CardioFocus collaborate to advance robotic PFA technology
- Stereotaxis announces procedures using Genesis at Erasmus Medical Center